Evolent Health (EVH) Stock Price, News & Analysis

Company Overview

Evolent Health (NYSE:EVH) is a technology‐enabled services company focused on transforming healthcare delivery through value-based care. Founded in 2011 as a business unit of The Advisory Board Company and spun off via IPO in 2018, Evolent partners with health systems and payers to help them assume risk and improve clinical outcomes while controlling costs. The company is headquartered in Arlington, Virginia and employs a multidisciplinary team of clinicians, technologists and operations experts.

At its core, Evolent Health supports clients in designing, launching and managing value-based care models across Medicare Advantage, Medicaid and commercial segments. Evolent helps organizations transition from fee-for-service to population-based reimbursement by providing care management programs, clinical protocols and actuarial guidance. Its framework enables payers and provider groups to coordinate care, engage patients and drive quality improvements.

Evolent’s suite of solutions encompasses technology platforms and consulting services. The company’s Evolent Risk Manager leverages data analytics to forecast and manage financial performance under risk contracts. Its Care Manager application supports outreach and utilization management, while the Coding Manager drives compliance and accurate risk adjustment. Evolent also offers advanced analytics, regulatory support and performance-benchmarking tools designed to optimize both clinical and financial outcomes.

Serving clients across the United States, Evolent Health works with more than 40 payer and provider organizations in both urban and rural markets. The leadership team is led by President and Chief Executive Officer Frank Williams, who brings decades of experience in managed care innovation, and Chief Financial Officer John Obermeyer, who oversees the company’s financial strategy. Together, they guide Evolent’s mission to improve population health and lower healthcare costs through sustainable value-based partnerships.

Key Stats

• Today's Range: $11.61 to $11.92
• 50-Day Range: $7.19 to $11.79
• 52-Week Range: $7.06 to $33.63
• Volume: 1.47 million shs
• Average Volume: 2.52 million shs
• Market Capitalization: $1.38 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.79
• Consensus Rating: Buy

Evolent Health Stock Analysis - MarketRank™

Evolent Health scored higher than 35% of companies evaluated by MarketBeat, and ranked 490th out of 663 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evolent Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Evolent Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evolent Health are expected to decrease in the coming year, from $0.08 to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolent Health is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolent Health is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evolent Health has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.16% of the float of Evolent Health has been sold short.

Short Interest Ratio / Days to Cover

Evolent Health has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Evolent Health has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolent Health does not currently pay a dividend.

Dividend Growth

Evolent Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.16% of the float of Evolent Health has been sold short.

Short Interest Ratio / Days to Cover

Evolent Health has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Evolent Health has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.15

News Sentiment

Evolent Health has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Evolent Health this week, compared to 7 articles on an average week.

Search Interest

3 people have searched for EVH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Evolent Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evolent Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of Evolent Health is held by insiders.

EVH Stock Analysis - Frequently Asked Questions

How have EVH shares performed this year?

Evolent Health's stock was trading at $11.25 at the beginning of 2025. Since then, EVH stock has increased by 4.8% and is now trading at $11.79.

How were Evolent Health's earnings last quarter?

Evolent Health, Inc (NYSE:EVH) announced its earnings results on Thursday, May, 8th. The technology company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The firm's quarterly revenue was down 24.4% compared to the same quarter last year.
Read the conference call transcript.

When did Evolent Health IPO?

Evolent Health (EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

How do I buy shares of Evolent Health?

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evolent Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolent Health investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Computer and Technology
• Industry: INTERNET SOFTWARE
• Sub-Industry: Business Services
• Current Symbol: NYSE:EVH
• CIK: 1628908
• Web: www.evolenthealth.com
• Phone: (571) 389-6000
• Fax: 571-389-6001
• Employees: 4,500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.79
• High Stock Price Target: $35.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +50.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 147.38
• P/E Growth: N/A
• Net Income: -$61.62 million
• Net Margins: -4.54%
• Pretax Margin: -4.56%
• Return on Equity: 3.64%
• Return on Assets: 1.44%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 0.98
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $2.55 billion
• Price / Sales: 0.54
• Cash Flow: $1.52 per share
• Price / Cash Flow: 7.77
• Book Value: $8.70 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 117,400,000
• Free Float: 115,756,000
• Market Cap: $1.38 billion
• Optionable: Optionable
• Beta: 1.01